Serum CA125 level is a good prognostic indicator in lung cancer

Kimura, Yoshiyuki; Fujii, Tetsuya; Hamamoto, Kohei; Miyagawa, N; Kataoka, Makoto; A, Iio

doi:10.1038/bjc.1990.355

Cited by 48 publications

(21 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We have thus concluded that the increase in CA 125 in these breast cancer patients was caused by the metastatic infiltration of either the lung or the pleura: only in those patients with pleural involvement were CA 125 levels elevated; CA 125 levels in patients with no pleural involvement remained low. This hypothesis is further substantiated by reports indicating that CA 125 levels are elevated in patients with primary lung cancer predominantly when the pleura is affected (Niwa & Shimokata, 1986, Van Niekerk et al, 1989Kandylis et al, 1990;Kimura et al, 1990;Diez et al, 1991).…”

supporting

confidence: 58%

See 1 more Smart Citation

Is an increase in CA 125 in breast cancer patients an indicator of pleural metastases?

Jäger

Kissing²,

Cilaci³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

S_lThe retrospective analysis of 250 breast cancer patients with disseminated disease provided evidence that the increase in CA 125 serum levels in these patients was caused by lung metastases or pleural effusions. Seven patients with lung metastases and pleural involvement had elevated CA 125 levels, while in four patients with lung metastases but without pleural effusions CA 125 levels remained normal. In patients with only bone or liver metastases ResultsOf a group of 250 patients with disseminated breast cancer, only 26 fulfilled the inclusion criteria. Most patients were excluded because multiple metastases were detected or could not be ruled out within 6 months after the detection of the first metastases. The final distribution of isolated metastases in these 26 patients was as follows: bone = nine patients (premenopausal: two patients), liver = six patients (premenopausal: four patients) and lung= 11 patients (premenopausal: five patients).The CA 125 levels at the time of detection of these metastases are shown in Figure 1. As can be seen, 7 of the 11 patients with lung metastases had elevated CA 125 serum levels (three premenopausal and four post-menopausal patients), while only one of nine patients with bone metastases (post-menopausal patient) and one out of six patients with liver metastases had high CA 125 levels (post-menopausal patient). Of the seven patients with lung metastases and elevated CA 125 levels, five had pleural effusions when the metastases were detected. The other two patients developed a pleuritis carcinomatosa with pleural effusions within 4 weeks of the diagnosis of the lung metastasis. The remaining four patients with normal CA 125 levels did not develop pleural effusions. The patient with high CA 125 levels and bone metastasis was shown post mortem (7 months later) to have pleuritis carcinomatosa, which had not been previously detected. The serial CA 125 measurements showed that in some patients the CA 125 concentration increased months before the detection of the metastasis (Figure 2). In the one patient with a liver metastasis and elevation of CA 125, the endocrine and metabolic function of the liver was impaired. In this patient serum aspartate transaminase (AST), serum alanine transaminase (ALT) and serum glutamyl transferase (GGT) were elevated.

show abstract

supporting

confidence: 58%

“…The shaded areas denote the normal concentrations for post-(<35 kU 1') and premenopausal (<65 kU I-') patients. Kandylis et al, 1990;Kimura et al, 1990;Diez et al, 1991). In contrast, elevated levels of CA 125 in patients with bone tumours have been reported only in patients with disseminated metastatic disease; in primary bone cancer, e.g.…”

mentioning

confidence: 99%

Is an increase in CA 125 in breast cancer patients an indicator of pleural metastases?

Jäger

Kissing²,

Cilaci³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Evidence concerning the clinical value of CA125 is also remarkable and, again, it is mainly due to one group of investigators (Diez et al, 1991(Diez et al, , 1996Picardo et al, 1994). Like TPA, the concentration of CA125 in the sera or in tumour cell cytosols of lung cancer patients has been found increased in the most advanced stages of disease (Diez et al, 1991;Kimura et al, 1990;Picardo et al, 1994) and prognostically significant (Diez et al, , 1996.…”

Section: Discussionmentioning

confidence: 99%

Lung tumour markers in oncology practice: a study of TPA and CA125

Buccheri

Ferrigno

2002

Br J Cancer

View full text Add to dashboard Cite

Several substances mark the course of lung cancer and may reliably help the clinician in decision-making. This is the first clinical study specifically designed to compare tissue polypeptide antigen and CA 125 tumour associated antigen. Three hundred and eighty-four new lung cancer patients (309 males) were studied at their first clinical presentation and then strictly followed-up. Anthropometric, clinical and laboratory data -including tissue polypeptide antigen and CA 125 tumour associated antigen serum levels -were prospectively recorded. A total of 1000 tissue polypeptide antigen and CA 125 tumour associated antigen serum assays (384 pre-treatment and 616 posttreatment assays) were performed. Both tissue polypeptide antigen and CA 125 tumour associated antigen correlated significantly with the T, N and M stage descriptors at diagnosis (Rho: 0.200, 0.203, 0.263 and 0.181, 0.240, 0.276, respectively), and then with the objective response to treatment (Rho: 0.388 and 0.207, respectively). A pleural neoplastic involvement was mainly associated to an increase of CA 125 tumour associated antigen (Rho: 0.397). Both tissue polypeptide antigen and CA 125 tumour associated antigen were strongly predictive of the patients' outcome, as assessed by the univariate analysis of survival (log-rank test: 37.24 and 29.01) and several Cox' proportional hazards regression models. The two marker tests are similarly helpful and appear complementary, given the low inter-marker correlation and their independent prognostic capability.

show abstract

“…CA125 expression in lung cancer cells has previously been reported and the accumulated data suggested that this tumor marker may be of significance for lung cancer therapy (6). Furthermore, CA125 expression in lung cancer patients may be a good predictive tool for patient outcome (17).…”

Section: Discussionmentioning

confidence: 99%

“…CA125 is a glycoprotein found on the cell membrane which has been used as a standard tumor marker for the diagnosis and follow-up of ovarian cancers (4,5). Moreover, a significant increase of CA125 has been reported in other cancers including breast and lung cancers has been noted (6,7).…”

Section: Introductionmentioning

confidence: 99%

Expression of CA125 and cisplatin susceptibility of pleural effusion-derived human lung cancer cells from a Thai patient

et al. 2012

View full text Add to dashboard Cite

Abstract. Advances in understanding lung cancer biology and tumor markers aid clinicians in managing the disease. Cancer-associated antigen (CA)125 has garnered increasing attention in lung cancer research and may benefit the treatment and follow-up of this type of cancer. In Thai lung cancer patients, knowledge regarding ethnic differences in cancer cell biology is largely absent. We generated lung cancer cells from the pleural effusion fluids of a Thai patient and designated these as P1 cells. P1 cells were assessed for growth rate, response to chemotherapy, and the presence of tumor markers, in particular CA125 expression. Results of immunofluorescence indicated that P1 cells exhibited strong expression levels of CA125, comparable to that of established H460 lung cancer cells. Furthermore, P1 cells were analyzed for the expression of additional markers. Results revealed that H460 cells exhibited strong immunofluorescent signals from cytokeratin-19 fragments (CYFRA 21-1) and squamous cell carcinoma antigen (SCCA) while P1 presented only CYFRA 21-1 signals. We also found evidence of relative cisplatin resistance in P1 compared to the susceptibility level of established lung cancer cells. Thus, the results and methodology described in this study may aid the development of lung cancer diagnostic and therapeutic approaches and, in particular, advance understanding of ethnic differences.

show abstract

Serum CA125 level is a good prognostic indicator in lung cancer

Cited by 48 publications

References 8 publications

Is an increase in CA 125 in breast cancer patients an indicator of pleural metastases?

Is an increase in CA 125 in breast cancer patients an indicator of pleural metastases?

Lung tumour markers in oncology practice: a study of TPA and CA125

Expression of CA125 and cisplatin susceptibility of pleural effusion-derived human lung cancer cells from a Thai patient

Contact Info

Product

Resources

About